Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Sutro Biopharma’s Xpress CF+™ Technology Nominated for Best Scientific Innovation by World ADC

Events

Sutro Biopharma’s Xpress CF+™ Technology Nominated for Best Scientific Innovation by World ADC On July 1, 2014, World ADC announced the nominees for the World ADC Awards, 2014. Sutro Biopharma’s cell free expression system, Xpress CF+™, has made the...

EnWave Signs Commercial License with Sutro Biopharma for powderREV® Technology

Events, News

EnWave Signs Commercial License with Sutro Biopharma for powderREV® Technology Press release published by EnWave Corporation regarding the recent agreement with Sutro Biopharma, Inc. Read...

Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference

Press Releases

Sutro Biopharma to Present at 21st Annual Future Leaders in the Biotech Industry Conference SAN FRANCISCO, Mar. 24, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug...

Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma

Press Releases

Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma SAN FRANCISCO, Jan. 07, 2014 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein...

Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products

Press Releases

Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products SAN FRANCISCO, Dec. 11, 2013 – Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will...

World ADC Summit 2013 – Dual-Warhead Antibody Drug Conjugate

Presentations

World ADC Summit 2013 – Dual-Warhead Antibody Drug Conjugate SAN FRANCISCO, Oct. 15, 2013 – Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics utilizing Sutro’s cell-free protein synthesis technology,...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.